Prolyl Carboxypeptidase Activity Decline Correlates with Severity and Short-Term Outcome in Acute Ischemic Stroke

Neurochemical Research

Volumn 40, Issue 1, 2015, Pages 81-88

  Kehoe, Kaat ^a   Brouns, Raf ^b   Verkerk, Robert ^a   Engelborghs, Sebastiaan ^c,d   De Deyn, Peter Paul ^c,d   Hendriks, Dirk ^a   De Meester, Ingrid ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^c Memory Clinic   (Belgium)

^d UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Acute ischemic stroke; Angiotensin; Angiotensinase C; Enzyme activity; Prolyl carboxypeptidase

Indexed keywords

C REACTIVE PROTEIN; PROLINE CARBOXYPEPTIDASE; CARBOXYPEPTIDASE; LYSOSOMAL PRO-X CARBOXYPEPTIDASE;

AGED; ALCOHOL ABUSE; ARTICLE; BLOOD SAMPLING; BODY MASS; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DYSLIPIDEMIA; ENZYME ACTIVITY; FEMALE; GLUCOSE BLOOD LEVEL; HEART FAILURE; HEART INFARCTION; HEART RATE; HOSPITAL ADMISSION; HUMAN; HYDROLYSIS; HYPERTENSION; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PLASMA VOLUME; PRIORITY JOURNAL; RANKIN SCALE; SMOKING; STROKE PATIENT; SYSTOLIC BLOOD PRESSURE; BLOOD; DISEASE COURSE; ENZYMOLOGY; METABOLISM; PATHOLOGY; RISK FACTOR; TREATMENT OUTCOME;

AGED; BRAIN ISCHEMIA; CARBOXYPEPTIDASES; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; RISK FACTORS; STROKE; TREATMENT OUTCOME;

EID: 84922071060     PISSN: 03643190     EISSN: 15736903     Source Type: Journal    
DOI: 10.1007/s11064-014-1468-y     Document Type: Article

References (40)

1. Donnan GA, Fisher M, Macleod M, Davis SM (2008) Stroke Lancet 371:1612–1623
2. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Turner MB et al (2013) Heart disease and stroke statistics–2013 update: a report from the American Heart Association. Circulation 127:e6–e245
3. Brouns R, De Deyn PP (2009) The complexity of neurobiological processes in acute ischemic stroke. Clin Neurol Neurosurg 111:483–495
4. Dirnagl U, Iadecola C, Moskowitz MA (1999) Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 22:391–397
5. Sugawara T, Fujimura M, Noshita N, Kim GW, Saito A, Hayashi T, Narasimhan P, Maier CM, Chan PH (2004) Neuronal death/survival signaling pathways in cerebral ischemia. NeuroRx 1:17–25
6. Brouns R, Heylen E, Willemse JL, Sheorajpanday R, De Surgeloose D, Verkerk R, De Deyn PP, Hendriks DF (2010) The decrease in procarboxypeptidase U (TAFI) concentration in acute ischemic stroke correlates with stroke severity, evolution and outcome. J Thromb Haemost 8:75–80
7. O’Donoghue AJ, Eroy-reveles AA, Knudsen GM, Ingram J, Zhou M, Statnekov JB, Greninger AL, Hostetter DR, Qu G, Maltby DA, Anderson MO, DeRIsi JL, Mckerrow JH, Burlingame AL, Craik CS (2013) Global identification of peptidase specificity by multiplex substrate profiling. Nat Methods 9:1095–1100
8. Mallela J, Yang J, Shariat-Madar Z (2009) Prolylcarboxypeptidase: a cardioprotective enzyme. Int J Biochem Cell Biol 41:477–481
9. Skidgel RA, Erdös EG (1998) Cellular carboxypeptidases. Immunol Rev 161:129–141
10. Shariat-Madar Z, Mahdi F, Schmaier AH (2004) Recombinant prolylcarboxypeptidase activates plasma prekallikrein. Blood 103:4554–4561
11. Chajkowski SM, Mallela J, Watson DE, Wang J, McCurdy CR, Rimoldi JM, Shariat-Madar Z (2011) Highly selective hydrolysis of kinins by recombinant prolylcarboxypeptidase. Biochem Biophys Res Commun 405:338–343
12. Shariat-Madar Z, Rahimy E, Mahdi F, Schmaier AH (2005) Overexpression of prolylcarboxypeptidase enhances plasma prekallikrein activation on Chinese hamster ovary cells. Am J Physiol Heart Circ Physiol 289:H2697–H2703
13. Wallingford N, Perroud B, Gao Q, Coppola A, Gyengesi E, Liu ZW, Goa XB, Diament A, Haus KA, Shariat-Madar Z, Mahdi F, Wardlaw SL, Schmaier AH, Warden CH, Diano S (2009) Prolylcarboxypeptidase regulates food intake by inactivating α-MSH in rodents. J Clin Invest 119:2291–2303
14. Palmiter RD (2009) Reduced levels of neurotransmitter-degrading enzyme PRCP promote obesity. J Clin Invest 119:2130–2133
15. Adams GN, LaRusch GA, Stavrou E, Zhou Y, Nieman MT, Jacobs GH, Cui Y, Lu Y, Jain MK, Mahdi F, Shariat-Madar Z, Okada Y, D’Alecy LG, Schmaier AH (2011) Murine prolylcarboxypeptidase depletion induces vascular dysfunction with hypertension and faster arterial thrombosis. Blood 117:3929–3937
16. Wang L, Feng Y, Zhang Y, Zhou H, Jiang S, Niu T, Wei LJ, Xu X, Xu X, Wang X (2006) Prolylcarboxypeptidase gene, chronic hypertension, and risk of preeclampsia. Am J Obstet Gynecol 195:162–171
17. Ngo ML, Mahdi F, Kolte D, Shariat-Madar Z (2009) Upregulation of prolylcarboxypeptidase (PRCP) in lipopolysaccharide (LPS) treated endothelium promotes inflammation. J Inflamm 6:3
18. Zhu L, Carretero OA, Liao TD, Harding P, Li H, Sumners C, Yang XP (2010) Role of prolylcarboxypeptidase in angiotensin II type 2 receptor-mediated bradykinin release in mouse coronary artery endothelial cells. Hypertension 56:384–390
19. Zhang Y, Hong XM, Xing HX, Li JP, Huo Y, Xu XP (2009) E112D polymorphism in the prolylcarboxypeptidase gene is associated with blood pressure response to benzapril in Chinese hypertensive patients. Chin Med J 122:2461–2465
20. Xu S, Lind L, Zhao L, Lindahl B, Venge P (2012) Plasma prolylcarboxypeptidase (angiotensinase C) is increased in obesity and diabetes mellitus and related to cardiovascular dysfunction. Clin Chem 58:1110–1115
21. Rabey FM, Gadepalli RSVS, Diano S, Cheng Q, Tabrizian T, Gailani D, Rimoldi JM, Shariat-Madar Z (2012) Influence of a novel inhibitor (UM8190) of prolylcarboxypeptidase (PRCP) on appetite and thrombosis. Curr Med Chem 19:4194–4206
22. Renna R, Pilato F, Profice P, Marca GD, Broccolini A, Morosetti R, Frisullo G, Rossi E, De Stefano V, Di Lazzaro V (2014) Risk factor and etiology analysis of ischemic stroke in young adult patients. J Stroke Cerebrovasc Dis 23:1–7
23. Shariat-Madar Z, Mahdi F, Schmaier AH (2002) Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator. J Biol Chem 277:17962–17969
24. Kehoe K, Verkerk R, Sim Y, Waumans Y, Van der Veken P, Lambeir AM, De Meester I (2013) Validation of a specific prolylcarboxypeptidase activity assay and its suitability for plasma and serum measurements. Anal Biochem 443:232–239
25. Jeong JK, Diano S (2014) Prolyl carboxypeptidase mRNA expression in the mouse brain. Brain Res 1542:85–92
26. Buga AM, Scholz CJ, Kumar S, Herndon JG, Alexandru D, Cojocaru GR, Dandekar T, Popa-Wagner A (2012) Identification of new therapeutic targets by genome-wide analysis of gene expression in the ipsilateral cortex of aged rats after stroke. PLoS One 7:e50985
27. Adams GN, Stavrou EX, Fang C, Merkulova A, Alaiti MA, Nakajima K, Morooka T, Merkulov S, LaRusch GA, Simon DI, Jain MK, Schmaier AH (2013) Prolylcarboxypeptidase promotes angiogenesis and vascular repair. Blood 122:1522–1531
28. Willemse JL, Brouns R, Heylen E, De Deyn PP, Hendriks DF (2008) Carboxypeptidase U (TAFIa) activity is induced in vivo in ischemic stroke patients receiving thrombolytic therapy. J Thromb Haemost 6:200–202
29. Brouns R, Heylen E, Sheorajpanday R, Willemse JL, Kunnen J, De Surgeloose D, Hendriks DF, De Deyn PP (2009) Carboxypeptidase U (TAFIa) decreases the efficacy of thrombolytic therapy in ischemic stroke patients. Clin Neurol Neurosurg 111:165–170
30. Brouns R, Sheorajpanday R, Wauters A, De Surgeloose D, Mariën P, De Deyn PP (2008) Evaluation of lactate as a marker of metabolic stress and cause of secondary damage in acute ischemic stroke or TIA. Clin Chim Acta 397:27–31
31. Brouns R, Marescau B, Possemiers I, Sheorajpanday R, De Deyn PP (2009) Dimethylarginine levels in cerebrospinal fluid of hyperacute ischemic stroke patients are associated with stroke severity. Neurochem Res 34:1642–1649
32. Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE (1993) Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24:35–41
33. Birschel P, Ellul J, Barer D (2004) Progressing stroke: towards an internationally agreed definition. Cerebrovasc Dis 17:242–252
34. Uyttenboogaart M, Luijckx GJ, Vroomen PCAJ, Stewart RE, De Keyser J (2007) Measuring disability in stroke: relationship between the modified Rankin scale and the Barthel index. J Neurol 254:1113–1117
35. Selim M, Savitz S, Linfante I, Caplan L, Schlaug G (2005) Effect of pre-stroke use of ACE inhibitors on ischemic stroke severity. BMC Neurol 5:10
36. Manabe Y, Kono S, Tanaka T, Narai H, Omori N (2009) High blood pressure in acute ischemic stroke and clinical outcome. Neurol Int 1:e1
37. Lu J, Jiang T, Wu L, Gao L, Wang Y, Zhou F, Zhang S, Zhang Y (2013) The expression of angiotensin-converting enzyme 2-angiotensin-(1-7)-Mas receptor axis are upregulated after acute cerebral ischemic stroke in rats. Neuropeptides 47:289–295
38. Gironacci MM, Carbajosa NAL, Goldstein J, Cerrato BD (2013) Neuromodulatory role of angiotensin-(1-7) in the central nervous system. Clin Sci (Lond) 125:57–65
39. Mecca AP, Regenhardt RW, O’Connor TE, Joseph JP, Raizada MK, Katovich MJ, Sumners C (2011) Cerebroprotection by angiotensin-1-7 in endothelin-1-induced ischaemic stroke. Exp Physiol 96:1084–1096
40. Blum A, Vaispapir V, Keinan-Boker L, Soboh S, Yehuda H, Tamir S (2012) Endothelial dysfunction and procoagulant activity in acute ischemic stroke. J Vasc Interv Neurol 5:33–39